www.biomedcentral.com

Table 1
Esophagus
Author	Cases n	Controls_a/Cohort_b	Source population	Exposure definition	Exposure assessment	Drug	RR	95% CI

Coogan et al. [26]	207	5,833_a	Hospital based	>4 days/week for >3 months. Continuing use during 1 year of lag time	Personal Interview	NSAIDs (7%)	0.8	0.5–1.4
Farrow et al. [30]	277	687_a	Population based	>1 tablet/week during >6 months. 1 year lag time	Personal Interview	Aspirin (31%)	0.48^†	0.32–0.70
	279					NA-NSAIDs (13%)	0.81^†	0.51–1.30
Langman et al. [36]	550	1,650_a	Population based	>7 prescriptions during months 13–36 before index date	Automated Database	NSAIDs (8%)	0.64	0.41–0.98
Garidou et al. [32]	56	200_a	Hospital based	Chronic intake	Personal Interview	NSAIDs (14%)	0.52^†	0.17–1.62
Suleiman et al. [59]	56	56_a	Population based	Ever use for >1 year	Medical records	NSAIDs (38%)	0.16	0.03–0.93
Cheng et al. [60]	74	74_a	Population based	Ever daily use for >1 month	Personal Interview	Aspirin (21%)	0.67	0.27–1.63
Funkhouser et al.³¹	15	13,179_b	Cohort	Use 30 days before baseline (ocasional)	Personal Interview	Aspirin (51%)	0.10	0.01–0.76
Thun et al. [46]	157	635,031_b	Cohort	More than 16 times per month for at least one year	Mailed questionnaire	Aspirin (11%)	0.59	0.34–1.03

Prevalence of exposure among controls/cohort; ^†Adenocarcinoma.
González-Pérez et al. BMC Cancer 2003 3:28 doi:10.1186/1471-2407-3-28

Table 1